What are IDH1 inhibitor drugs?

IDH1 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting IDH1 (isocitrate dehydrogenase 1, mutant)). 0 are currently marketed, with 2 more in clinical development.

IDH1 inhibitor

0 marketed 2 in Phase 3

This page covers all IDH1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IDH1 (isocitrate dehydrogenase 1, mutant), IDH1 (isocitrate dehydrogenase 1).

Targets

IDH1 (isocitrate dehydrogenase 1, mutant) · IDH1 (isocitrate dehydrogenase 1)

Phase 3 pipeline (2)

Ivosidenib Oral Tablet · Servier Bio-Innovation LLC · Oncology
Ivosidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) that blocks the production of the oncometabolite 2-hydroxyglutarate, thereby promoting differentiation and apoptosis of IDH1-mutant cancer cells.
AG-120 · Institut de Recherches Internationales Servier · Oncology
AG-120 is an isocitrate dehydrogenase 1 (IDH1) inhibitor that blocks the production of the oncometabolite 2-hydroxyglutarate in IDH1-mutant cancers.